1-11 of 11
Bin Fan
Close
Sort by
Journal Articles

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Clinical Trials & Observations
Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi, Alice S. Mims, Keith W. Pratz, Michael R. Savona, Anthony S. Stein, Richard M. Stone, Eric S. Winer, Christopher S. Seet, Hartmut Döhner, Daniel A. Pollyea, James K. McCloskey, Olatoyosi Odenike, Bob Löwenberg, Gert J. Ossenkoppele, Prapti A. Patel, Mikhail Roshal, Mark G. Frattini, Frederik Lersch, Aleksandra Franovic, Salah Nabhan, Bin Fan, Sung Choe, Hongfang Wang, Bin Wu, Lei Hua, Caroline Almon, Michael Cooper, Hagop M. Kantarjian, Martin S. Tallman
Journal: Blood
Blood (2021) 137 (13): 1792–1803.
https://doi.org/10.1182/blood.2020007233
Published: 2021
Includes: Supplemental data
Journal Articles

Longitudinal Molecular Profiling in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib

Sung Choe, PhD, Hongfang Wang, PhD, Gail J. Roboz, MD, Courtney D. DiNardo, MD MSCE, Eytan M. Stein, MD, Alice S. Mims, MD, Gabrielle T. Prince, MD, Justin M. Watts, MD, Bin Fan, PhD, Parham Nejad, BSc, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD, Richard M. Stone, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-136589
Published: 2020
Journal Articles

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1 -mutant acute myeloid leukemia

Clinical Trials & Observations
Gail J. Roboz, Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, Martha L. Arellano, Will Donnellan, Harry P. Erba, Gabriel N. Mannis, Daniel A. Pollyea, Anthony S. Stein, Geoffrey L. Uy, Justin M. Watts, Amir T. Fathi, Hagop M. Kantarjian, Martin S. Tallman, Sung Choe, David Dai, Bin Fan, Hongfang Wang, Vickie Zhang, Katharine E. Yen, Stephanie M. Kapsalis, Denice Hickman, Hua Liu, Samuel V. Agresta, Bin Wu, Eyal C. Attar, Richard M. Stone
Journal: Blood
Blood (2020) 135 (7): 463–471.
https://doi.org/10.1182/blood.2019002140
Published: 2020
Includes: Supplemental data
Journal Articles

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

James M. Foran, MD, Courtney D. DiNardo, MDMSc, Justin M. Watts, MD, Eytan M. Stein, MD, Stephane De Botton, Amir T. Fathi, MD, Gabrielle T. Prince, MD, Anthony Stein, MD, Richard M. Stone, MD, Prapti A. Patel, MD, Martin S. Tallman, MD, Sung Choe, PhD, Hongfang Wang, PhD, Vickie Zhang, PhD, Bin Fan, PhD, Katharine E. Yen, PhD, Abdulafeez Oluyadi, PharmD, Thomas Winkler, MD, Denice Hickman, BSN, Samuel V. Agresta, MD, Hua Liu, PhD, Bin Wu, PhD, Eyal C. Attar, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4254.
https://doi.org/10.1182/blood-2019-123946
Published: 2019
Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study

Courtney D. DiNardo, MDMSc, Justin M. Watts, MD, Eytan M. Stein, MD, Stephane de Botton, MD PhD, Amir T. Fathi, MD, Gabrielle T. Prince, MD, Anthony S. Stein, MD, James M. Foran, MD, Richard M. Stone, MD, Prapti A. Patel, MD, Martin S. Tallman, MD, Sung Choe, PhD, Hongfang Wang, PhD, Vickie Zhang, PhD, David Dai, PhD, Bin Fan, PhD, Katharine E. Yen, PhD, Stephanie M. Kapsalis, OTR, Denice Hickman, RN, Samuel V. Agresta, MD, Hua Liu, PhD, Bin Wu, PhD, Eyal C. Attar, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1812.
https://doi.org/10.1182/blood-2018-99-111264
Published: 2018
Journal Articles

Population Pharmacokinetics of Ivosidenib (AG-120) in Patients with IDH1-Mutant Advanced Hematologic Malignancies

Kha Le, PhD, Russ Wada, PhD, David Dai, PhD, Bin Fan, PhD, Guowen Liu, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Samuel V. Agresta, MD, Hua Yang, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1394.
https://doi.org/10.1182/blood-2018-99-109863
Published: 2018
Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

Gail J. Roboz, MD, Courtney D. DiNardo, MDMSc, Eytan M. Stein, MD, Stephane de Botton, MD PhD, Alice S. Mims, MD, Gabrielle T. Prince, MD, Jessica K. Altman, MD, Martha L. Arellano, MD, William B. Donnellan, MD, Harry P. Erba, MD PhD, Gabriel N. Mannis, MD, Daniel A Pollyea, MD, Anthony S. Stein, MD, Geoffrey L. Uy, MD, Justin M. Watts, MD, Amir T. Fathi, MD, Hagop M. Kantarjian, MD, Martin S. Tallman, MD, Sung Choe, PhD, David Dai, PhD, Bin Fan, PhD, Hongfang Wang, PhD, Vickie Zhang, PhD, Katharine E. Yen, PhD, Stephanie M. Kapsalis, OTR, Denice Hickman, RN, Hua Liu, PhD, Samuel V. Agresta, MD, Bin Wu, PhD, Eyal C. Attar, MD, Richard M. Stone, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 561.
https://doi.org/10.1182/blood-2018-99-110595
Published: 2018
Journal Articles

Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies

Bin Fan, PhD, Kha Le, PhD, Erika Manyak, BASc, Hua Liu, Malia Prahl, Chris J Bowden, Scott Biller, Sam Agresta, MD, Hua Yang, PhD
Journal: Blood
Blood (2015) 126 (23): 1310.
https://doi.org/10.1182/blood.V126.23.1310.1310
Published: 2015
Journal Articles

Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial

Yue Gao, PhD, Bin Fan, PhD, Kha Le, PhD, Erika Manyak, BASc, Hua Yang, PhD, Katherine Yen, PhD, Sam Agresta, MD, Eyal C. Attar, MD, Jian Chen, PhD, Qiang Xu, PhD, Alessandra Tosolini, BS, Jay M. Mei, MD PhD, Anjan Thakurta, Robert D. Knight, MD, Yan Li, PhD
Journal: Blood
Blood (2015) 126 (23): 2509.
https://doi.org/10.1182/blood.V126.23.2509.2509
Published: 2015
Journal Articles

AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies

Eytan M. Stein, Jessica K Altman, Robert Collins, Daniel J DeAngelo, Amir T Fathi, Ian Flinn, Arthur Frankel, Ross L Levine, MD, Bruno C Medeiros, MD, Manish Patel, Daniel A Pollyea, Gail J. Roboz, MD, Richard M Stone, Ronan T Swords, MD PhD FRCPI, FRCPath, Martin S. Tallman, MD, Sam Agresta, Bin Fan, Hua Yang, Katharine Yen, Stéphane de Botton
Journal: Blood
Blood (2014) 124 (21): 115.
https://doi.org/10.1182/blood.V124.21.115.115
Published: 2014
Journal Articles

Evaluation of Pharmacokinetic-Pharmacodynamic (PKPD) Relationship of an Oral, Selective, First-in-Class, Potent IDH2 Inhibitor, AG-221, from a Phase 1 Trial in Patients with Advanced IDH2 Mutant Positive Hematologic Malignancies

Bin Fan, Yue Chen, Fang Wang, Katharine Yen, Luke Utley, Caroline Almon, Scott Biller, Sam Agresta, Hua Yang
Journal: Blood
Blood (2014) 124 (21): 3737.
https://doi.org/10.1182/blood.V124.21.3737.3737
Published: 2014